The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Menarini; Menarini; Menarini; Menarini
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
 
Hongjae Chon
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Menarini; Menarini; Menarini; Menarini; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Sillajen; Sillajen; Sillajen; Sillajen
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Menarini; Menarini; Menarini; Menarini; Sanofi; Sanofi; Sanofi; Sanofi
Research Funding - Sillajen; Sillajen; Sillajen; Sillajen
 
Chang Gon Kim
No Relationships to Disclose
 
Sangeun Yoon
No Relationships to Disclose
 
Chan Kim
Research Funding - Sillajen; Sillajen; Sillajen; Sillajen
 
Beodeul Kang
No Relationships to Disclose
 
Hye Jin Choi
Consulting or Advisory Role - Bayer Health; Bayer Health; Bayer Health; Bayer Health; Bristol-Myers Squibb (Mexico); Bristol-Myers Squibb (Mexico); Bristol-Myers Squibb (Mexico); Bristol-Myers Squibb (Mexico); MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
 
Ho Yeong Lim
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Eisai; Eisai; Eisai; Eisai; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai